Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticle Delivery Increases Effectiveness of Anti-Cancer Immunotherapy

By LabMedica International staff writers
Posted on 10 May 2018
A nanoparticle delivery system was used to transport antibody-based immunotherapeutic drugs in trials conducted in cancer cell in vitro cultures and in animal models.

Combination immunotherapy has recently emerged as a powerful cancer treatment strategy. More...
A promising treatment approach is based on the simultaneous administration of antagonistic antibodies to block checkpoint inhibitor receptors, such as anti-programmed cell death‐1 (PD1). Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately.

In this treatment strategy, antibodies targeting checkpoint inhibitor receptors are given together with agonistic antibodies to activate co-stimulatory receptors, such as anti-tumor necrosis factor receptor superfamily member 4 (OX40). OX40's value as a drug target resides primarily in it being transiently expressed after T-cell receptor engagement. It is only upregulated on the most recently antigen-activated T-cells within inflammatory lesions.

Optimal T‐cell activation is achieved when both immunomodulatory agents simultaneously engage T‐cells and promote synergistic pro-activation signaling. However, standard administration of these therapeutics as free antibodies results in suboptimal T‐cell binding events, with only a subset of the T‐cells binding to both PD1 and OX40.

To increase the changes of simultaneous binding of both classes of antibody, investigators at the University of North Carolina (Chapel Hill, USA) developed nanoparticles capable of simultaneous co-delivery of antibodies to PD1 and OX40.

They reported in the April 25, 2018, online edition of the journal Advanced Materials that using these dual immunotherapy nanoparticles (DINP) resulted in improved T‐cell activation, enhanced therapeutic efficacy, and increased immunological memory. They demonstrated that DINP elicited higher rates of T‐cell activation in vitro than free antibodies. Furthermore, they showed in two tumor models that combination immunotherapy administered in the form of DINP was more effective than the same regimen administered as free antibodies.

"Our study suggests that if you are able to present two different therapeutics at the same time to immune cells to help them fight cancer, the effect is greater," said senior author Dr. Andrew Z. Wang, associate professor of radiation oncology at the University of North Carolina. "It is difficult to deliver them at the same time unless you tie them together, and a nanoparticle is one great way to tie the two together."

"Our immune cells have both positive and negative signals, like red lights and green lights," said Dr. Wang. "It is part of the balance of the immune system - if you get too much immune activation, you get autoimmune disease. If you go the other way, the lack of immune suppression can give you tumors. We are studying a combination of treatments that both send green light signals to attack, and to block red light signals."

Related Links:
University of North Carolina


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.